Literature DB >> 25949527

From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease.

Charles W Randall1, John A Vizuete2, Nicholas Martinez3, John J Alvarez3, Karthik V Garapati3, Mazyar Malakouti3, Carlo M Taboada1.   

Abstract

Crohn's disease (CD) is a debilitating, systemic inflammatory disorder with both gastrointestinal and extraintestinal manifestations. Its existence predates modern medicine, but its precise etiology remains incompletely understood. Most authorities suggest a multifactorial pathogenesis owing to a mixture of genetic disorders, immunologic dysregulation, microbiota disequilibrium and environmental influences. Of these factors, the overactive immunologic response seen in CD appears to be the most promising target of medical therapy. Biological agents comprise a relatively new class of drugs that can induce and maintain remission in moderate to severe CD, as well as in ulcerative colitis. This review will provide an overview of CD, its history, clinical features, pathophysiology, and treatment options focusing on current and future biological agents with an emphasis on drug development, dosage and administration.

Entities:  

Keywords:  Crohn’s Disease; Inflammatory Bowel Disease; anti-TNF; biologics

Year:  2015        PMID: 25949527      PMCID: PMC4416294          DOI: 10.1177/1756283X15576462

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  107 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis.

Authors:  H E LOCKHART-MUMMERY; B C MORSON
Journal:  Gut       Date:  1960-06       Impact factor: 23.059

3.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

4.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

5.  Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

Authors:  A Vultaggio; A Matucci; F Nencini; S Pratesi; P Parronchi; O Rossi; S Romagnani; E Maggi
Journal:  Allergy       Date:  2009-11-27       Impact factor: 13.146

6.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Authors:  Y Bouhnik; M Lémann; J Y Mary; G Scemama; R Taï; C Matuchansky; R Modigliani; J C Rambaud
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

7.  Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.

Authors:  Zuzana Zelinkova; Cokkie van der Ent; Karlien F Bruin; Onno van Baalen; Hestia G Vermeulen; Herman J T Smalbraak; Rob J Ouwendijk; Aad C Hoek; Sjoerd D van der Werf; Ernst J Kuipers; C Janneke van der Woude
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-25       Impact factor: 11.382

8.  Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.

Authors:  Atsushi Sakuraba; Maria L Annunziata; Russell D Cohen; Stephen B Hanauer; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2013-11       Impact factor: 5.325

9.  Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Matthieu Allez; Jean-Louis Dupas; Olivier Dewit; Geert D'Haens; Yoram Bouhnik; Gerald Parker; Bosny Pierre-Louis; Xavier Hébuterne
Journal:  Clin Gastroenterol Hepatol       Date:  2013-11-01       Impact factor: 11.382

10.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  9 in total

1.  Identification of a Disease-Associated Network of Intestinal Immune Cells in Treatment-Naive Inflammatory Bowel Disease.

Authors:  Vincent van Unen; Laura F Ouboter; Na Li; Mette Schreurs; Tamim Abdelaal; Yvonne Kooy-Winkelaar; Guillaume Beyrend; Thomas Höllt; P W Jeroen Maljaars; M Luisa Mearin; Ahmed Mahfouz; Anne M C Witte; Cornelis H M Clemens; Sunje Abraham; Johanna C Escher; Boudewijn P F Lelieveldt; M Fernanda Pascutti; Andrea E van der Meulen-de Jong; Frits Koning
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 2.  Rectovaginal Fistula in Crohn's Disease: When and How to Operate?

Authors:  Jeremy Meyer; Frédéric Ris; Miles Parkes; Justin Davies
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

Review 3.  Magnetic resonance enterography in Crohn's disease: How we do it and common imaging findings.

Authors:  Annalisa Mantarro; Paola Scalise; Elisa Guidi; Emanuele Neri
Journal:  World J Radiol       Date:  2017-02-28

4.  Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.

Authors:  J Scott Crowe; Kevin J Roberts; Timothy M Carlton; Luana Maggiore; Marion F Cubitt; Simon Clare; Katherine Harcourt; Jill Reckless; Thomas T MacDonald; Keith P Ray; Anna Vossenkämper; Michael R West
Journal:  Sci Rep       Date:  2018-03-21       Impact factor: 4.379

5.  Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.

Authors:  Matthew K Doherty; Tao Ding; Charlie Koumpouras; Shannon E Telesco; Calixte Monast; Anuk Das; Carrie Brodmerkel; Patrick D Schloss
Journal:  mBio       Date:  2018-03-13       Impact factor: 7.867

6.  Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation.

Authors:  Charlotte K Brierley; Cristina Castilla-Llorente; Myriam Labopin; Manuela Badoglio; Montserrat Rovira; Elena Ricart; Daan Dierickx; Severine Vermeire; Peter Hasselblatt; Juergen Finke; Francesco Onida; Andrea Cassinotti; Jack Satsangi; Majid Kazmi; Antonio López-Sanromán; Carsten Schmidt; Dominique Farge; Simon P L Travis; Chris J Hawkey; John A Snowden
Journal:  J Crohns Colitis       Date:  2018-08-29       Impact factor: 9.071

7.  Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients.

Authors:  Suhail Nurbhai; Kevin J Roberts; Timothy M Carlton; Luana Maggiore; Marion F Cubitt; Keith P Ray; Jill Reckless; Hafeez Mohammed; Peter Irving; Thomas T MacDonald; Anna Vossenkämper; Michael R West; Gareth C Parkes; J Scott Crowe
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

Review 8.  Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases.

Authors:  Jan Bilski; Agnieszka Mazur-Bialy; Dagmara Wojcik; Marcin Surmiak; Marcin Magierowski; Zbigniew Sliwowski; Robert Pajdo; Slawomir Kwiecien; Aleksandra Danielak; Agata Ptak-Belowska; Thomas Brzozowski
Journal:  Biomolecules       Date:  2019-11-26

9.  Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.

Authors:  G Monteleone; A Di Sabatino; S Ardizzone; F Pallone; K Usiskin; X Zhan; G Rossiter; M F Neurath
Journal:  Aliment Pharmacol Ther       Date:  2016-01-13       Impact factor: 8.171

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.